StockIQ.techZoetis Inc. (ZTS) Stock Analysis
Free AI-powered analysis and research for Zoetis Inc. stock
Sector: Healthcare
ZTS snapshot
Data as of 3 Nov 2026 close. Updated daily.
Zoetis Inc. scores 70/100 on StockIQ's model, which reads as positive signals overall. The price is below its 200-day average and at 19% of its 52-week range, down 42.4% over the past year. Latest reported figures show a profit margin of 27.7%, return on equity of 64.9% and revenue growth of -0.2%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- Low P/E (12.8): +10
- Excellent Profit Margin (27.7%): +10
- High Debt (2.94 D/E): -10
- Strong Liquidity (3.08 Current Ratio): +8
- Excellent ROE (64.9%): +8
- High P/B (10.24): -5
- Long-term Downtrend: -8
- Severe Underperformance (-42.4% over 1 year): -10
- Low Volume (0.4x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full ZTS report
Zoetis Inc. (ZTS) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze ZTS Now →📰 Latest Update
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
Tue, November 3, 2026 at 2:15 PM UTC 3 min read
Zoetis, Inc. (ZTS) is set to report its third-quarter earnings on Nov. 5, 2026, with revenue estimates at $2.30 billion and earnings at $1.51 per share. The U.S. segment is expected to see a revenue decline due to lower sales of companion animal products, while the International segment may experience growth from livestock and companion animal sales. Despite a challenging market, Zoetis' product portfolio, including its dermatology and parasiticide offerings, could support performance in the upcoming report.